Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2023-01-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于注销公司2018年（第二期）股票期权激励计划首次授予股票期权第三个行权期满未行权股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of unexercised stock options from a specific stock option incentive plan (2018 second phase). It details the board and supervisory meetings approving the cancellation, the number of options cancelled, and legal opinions supporting the action. The document does not contain financial statements or detailed financial performance data, nor is it a full report like an annual or interim report. It is a regulatory announcement about a corporate action related to stock options, specifically the cancellation of expired unexercised options. This fits best under the category of Regulatory Filings (RNS), as it is a compliance and disclosure announcement that does not fit other more specific categories such as capital changes (SHA) or director dealings (DIRS). The document length and detail also indicate it is not a brief announcement but a full regulatory disclosure. Therefore, the classification is RNS with high confidence.
2023-01-10 Chinese
关于终止向特定对象发行股票事项并撤回申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the termination of a previously planned private placement of shares and the withdrawal of the related application documents. It details board and supervisory committee meetings, independent directors' opinions, and the impact of the termination on the company. The document does not contain financial statements or detailed financial data but is a formal disclosure about a capital raising activity being stopped. This fits the category of a Capital/Financing Update (CAP) as it relates to changes in the company's financing plans and capital structure activities.
2023-01-10 Chinese
关于2023年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 贝达药业股份有限公司 regarding the expected daily related party transactions for the year 2023. It includes extensive information about the related parties, transaction amounts, pricing principles, and independent directors' opinions. The document references compliance with Shenzhen Stock Exchange listing rules and company bylaws, and it includes financial data of related parties and explanations of the transactions' necessity and fairness. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a call transcript, nor a management or investor presentation. The document is a formal announcement about expected related party transactions, which is a regulatory disclosure typically classified under Regulatory Filings (RNS) as it does not fit other specific categories like capital updates or board changes. The document length is over 11,000 characters, so it is not a brief report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2023-01-10 Chinese
第四届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a supervisory board meeting of a company, including election of the supervisory board chairman, approval of daily related party transactions, stock option cancellations, termination of a specific stock issuance, and related agreements. It includes voting results and references to other announcements for further details. The content focuses on board/supervisory board decisions and governance matters rather than financial results, audit opinions, or regulatory filings. It is not a full annual or interim report, nor an earnings release or capital update. The document is a formal announcement of board-level decisions and management information. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3071 characters, which is consistent with a detailed announcement rather than a full report.
2023-01-10 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting, including election of board chairman, appointment of senior management, approval of related party transactions, stock option cancellations, and termination of a specific stock issuance plan. It references compliance with company law and listing rules, and includes voting results for each agenda item. The content focuses on board and management changes and decisions rather than financial results or reports. There is no indication of financial statements or earnings data. The document is not a report itself but a formal announcement of board meeting decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length (5173 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2023-01-10 Chinese
关于BPI-460372片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 贝达药业股份有限公司 regarding the approval of a clinical trial for a new drug (BPI-460372) by the National Medical Products Administration (NMPA). It details the clinical trial approval notice, drug information, and potential impact on the company. The document is short (1251 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed study. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-01-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.